---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Expected outcomes of therapy"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Expected outcomes of therapy. Topics: Summary: expected outcomes, Inaxaplin: proteinuria reduction and the hypothesized effect on progression, AMPLITUDE: endpoints that will measure clinical outcomes, Albuminuria change as a surrogate endpoint: meta-analysis of 41 treatment comparisons, and 10 further topics. 14 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary: expected outcomes

AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio); [Heerspink et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30635226/); [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/); [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/); [Troost et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967666/); [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/); [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-2.2.2.7-2"></a>

### Inaxaplin: proteinuria reduction and the hypothesized effect on progression

> “For the 13 evaluable participants, the mean change in the urinary protein-to-creatinine ratio of −47.6% (95% confidence CI, −60.0 to −31.3) was observed at week 13.”
> “A reduction in proteinuria or albuminuria of more than 40% is considered to be clinically meaningful on the basis of data from nearly 30,000 patients, in whom a 30% reduction in albuminuria translated to a 27% reduction in the risk of a composite clinical end point of end-stage kidney disease, an estimated GFR below 15 ml per minute per 1.73 m2, or a doubling of the serum creatinine level (57% reduction in the estimated GFR).”
> “Collectively, these data provide a rationale to test the hypothesis that with a longer treatment period, inaxaplin therapy may prevent or slow progression to end-stage kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.7-3"></a>

### AMPLITUDE: endpoints that will measure clinical outcomes

> “The primary efficacy endpoint for the final analysis is estimated glomerular filtration rate (eGFR) slope in patients receiving inaxaplin compared to placebo after two years of treatment.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”
> “The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in the eGFR, the onset of end-stage kidney disease or death. The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.2.2.7-4"></a>

### Albuminuria change as a surrogate endpoint: meta-analysis of 41 treatment comparisons

> “We identified 41 eligible treatment comparisons from randomised trials (referred to as studies) that provided sufficient patient-level data on 29 979 participants (21 206 [71%] with diabetes).”
> “Across all studies, with a meta-regression slope of 0·89 (95% Bayesian credible interval [BCI] 0·13-1·70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was associated with an average 27% lower hazard for the clinical endpoint (95% BCI 5-45%; median R2 0·47, 95% BCI 0·02-0·96).”

Source: [Heerspink et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30635226/)

<a id="topic-2.2.2.7-5"></a>

### Albuminuria change as a surrogate endpoint: meta-analysis of 48 trials

> “Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.”
> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98). There was no clear evidence that this association varied by CKD etiology.”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-2.2.2.7-6"></a>

### GFR slope as a surrogate endpoint: meta-analysis of 66 studies

> “Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.”
> “indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%)”

Source: [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/)

<a id="topic-2.2.2.7-7"></a>

### Albuminuria and GFR slope as joint surrogate endpoints

> “The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up.”

Source: [Heerspink et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278784/)

<a id="topic-2.2.2.7-8"></a>

### National Kidney Foundation, FDA, and EMA scientific workshop on surrogate endpoints

> “In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to evaluate changes in albuminuria or GFR as candidate surrogate end points.”
> “We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.”

Source: [Levey et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31473020/)

<a id="topic-2.2.2.7-9"></a>

### Proteinuria remission and kidney survival in FSGS

> “A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77).”
> “Propensity score–adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002).”

Source: [Troost et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967666/)

> “A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).”
> “There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).”

Source: [Troost et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854818/)

<a id="topic-2.2.2.7-10"></a>

### Proteinuria endpoints in FSGS trials: Kidney Health Initiative review

> “Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

<a id="topic-2.2.2.7-11"></a>

### Reasonably likely surrogate endpoints and accelerated approval

> “We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment’s effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.”

Source: [Thompson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419287/)

<a id="topic-2.2.2.7-12"></a>

### Albuminuria change as a surrogate endpoint in AMKD: real-world analysis (preprint)

> “Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-2.2.2.7-13"></a>

### Expected benefits of an APOL1-targeted treatment: expert consensus

> “Important potential benefits of a treatment for APOL1-associated nephropathy becoming available include:”
> “Slowing kidney disease progression”
> “Extending life expectancy”
> “Reducing the incidence of ESKD in the Black population”
> “Reducing the number of people requiring a kidney transplant”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.7-14"></a>

### Untreated course against which benefit would be measured

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “For patients with baseline eGFR below 75 mL/min, the median time to a composite of a 30% or greater eGFR decline, end-stage kidney disease, or death ranged from 3 to 5 years across subgroups.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
